MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...

The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...

Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...

In the trial, most interstitial lung disease events were observed to be low grade, with two grade 5 ILD events being reported ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...